-
Richard Henderson,
Marshall founded Heptares Therapeutics, a spin-out from the
Medical Research Council (MRC).
Heptares makes use of
technologies developed...
-
operating businesses in ****an and
South Korea to the ****anese firm
Sosei Heptares for CHF 400 million. This
includes the
rights to
market clazosentan (Piviaz)...
-
breakup fee. In
April 2016, the
company announced it
would partner with
Heptares Therapeutics to
develop a subtype-selective
muscarinic agonists for Alzheimer's...
- Innovations. In
November 2015, the
company announced it
would collaborate with
Heptares Therapeutics with its work on small-molecule
calcitonin gene-related peptide...
-
announced it had
acquired the
global rights to
develop and
commercialise Heptares Therapeutics' drug
candidate HTL-1071,
which focuses on
blocking the adenosine...
- kingfaisalprize.org.
Retrieved 4
October 2018. "Scientific
Advisory Board".
Heptares.
Retrieved 5
April 2013. {{Google
Scholar ID}}
template missing ID and...
-
charity LifeArc,
Henderson and Tate
founded the MRC start-up company,
Heptares Therapeutics Ltd (HTL) in 2007. HTL
continues to
develop new
drugs targeting...
- and used as the
basis for the
foundation of the drug
discovery company Heptares Therapeutics Ltd (HTL) in July 2007 by Tate, Henderson,
Fiona Marshall...
-
faster biremes and triremes,
along with
various heavier combat ships, up to
Heptares class.
Additional points may be
spent to
upgrade individual ships, such...
- Life
Sciences (MPLS) Division.
Garman is the
first recipient of the
Sosei Heptares Prize,
awarded in July 2018. She
received an
honorary doctorate from Durham...
